The abstract is read at the publisher; the summary is JClub's.
Initiating oxycodone in adults with type 2 diabetes on GLP-1 receptor agonists is linked to higher 30-day motility-related GI event risk (0.51%) than hydrocodone (0.35%) or tramadol (0.33%).
- Why it matters: The GI safety of combining opioids with GLP-1 receptor agonists in type 2 diabetes is not well characterized, leaving uncertainty about short-term severe motility-related outcomes.
- What they did: In a U.S. population-based new-user claims cohort (2016–2025), adults with type 2 diabetes starting oxycodone, hydrocodone, or tramadol were compared using propensity score-matching weights for a composite of severe constipation, bowel obstruction, and gastroparesis.
- The result: Oxycodone showed higher risk versus hydrocodone (RR 1.48; RD 0.17) and versus tramadol (RR 1.55; RD 0.18), while hydrocodone and tramadol were similar (RR 1.05; RD 0.02); gastroparesis did not differ.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.